Canopy Growth Slides 9% as Q2 Loss Widens and Revenue Misses Estimates
CGC is trading near its 52-week low of $0.581 (5.8% above the low) on elevated volume (1.8× avg).
Summary
Canopy Growth posted a Q2 FY2027 loss of 7 cents a share versus the 3 cents analysts expected, and revenue of $58.149 million (C$81.4 million) came in below the $59.12 million estimate. The net loss widened by C$35.7 million, driven largely by C$35.8 million in non-cash fair value charges on Canopy USA assets. Cannabis revenue rose 30% to C$66.2 million and international revenue jumped 141% on German and Polish medical sales, but Storz & Bickel fell 4% to C$15.1 million and adjusted gross margin slipped to 31% from 33%. Adjusted EBITDA loss improved 6% to C$2.9 million, and the CFO said positive adjusted EBITDA is within reach in fiscal 2027. Shares were down 9.03% at $0.61 on 4.91 million shares, about 71.6% above the 100-day average, with the stock still under the Nasdaq $1.00 minimum-bid notice disclosed in the October 16 8-K and a shareholder-approved reverse split available at board discretion.
At the time of this announcement, CGC was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273.9M. The 52-week trading range was $0.58 to $2.38. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.